

DAFTAR PUSTAKA

- Agrawal, U., Raju, R. and Udwardia, Zarir F. (2020) 'Favipiravir: A new and emerging antiviral option in COVID-19', *Medical Journal Armed Forces India*. Elsevier B.V., pp. 370–376. doi: 10.1016/j.mjafi.2020.08.004.
- Agrawal, U., Raju, R. and Udwardia, Zarir F (2020) 'Favipiravir: A new and emerging antiviral option in COVID-19', *Medical Journal Armed Forces India*, 76, pp. 370–376. doi: 10.1016/j.mjafi.2020.08.004.
- Alamer, A., Alrashed, A. A., Alfaifi, M., Alosaimi, B., AlHassar, F., Almutairi, M., Howaidi, J., Almutairi, W., Mohzari, Y., Sulaiman, T., Al-jedai, A., Alajami, H. N., Alkharji, F., Alsaeed, A., Alali, A. H., Baredhwan, A. A., Abraham, I. and Almulhim, A. S. (2021) 'Effectiveness and safety of favipiravir compared to supportive care in moderately to critically ill COVID-19 patients: a retrospective study with propensity score matching sensitivity analysis', *Current Medical Research and Opinion*. Taylor & Francis, 37(7), p. 1. doi: 10.1080/03007995.2021.1920900.
- Anonim (2022a) *COVID-19 / Kabupaten Banyumas*. Available at: <http://covid19.banyumaskab.go.id/> (Accessed: 5 January 2022).
- Anonim (2022b) *Peta Sebaran / Covid19.go.id*. Available at: <https://covid19.go.id/peta-sebaran> (Accessed: 24 April 2022).
- Bosaeed, M., Alharbi, A., Mahmoud, E., Alrehily, S., Bahlaq, M., Gaifer, Z., Alturkistani, H., Alhagan, K., Alshahrani, S., Tolbah, A., Musattat, A., Alanazi, M., Jaha, R., Sultana, K., Alqahtani, H., Al Aamer, K., Jaser, S., Alsaedy, A., Ahmad, A., Abalkhail, M., Aljohani, S., Al Jeraisy, M., Albaalharith, N., Alabdulkareem, K., Alshowair, A., Khalaf Alharbi, N., Alrabiah, F., Alshamrani, M., Aldibasi, O. and Alaskar, A. (2021) 'Saudi Arabia 7) King Abdullah Medical CitydMakkah, Ministry of Health, Saudi Arabia 8) Pharmaceutical Care Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia 9) Infection Prevention and Control Program, Ministry of National Guard Health Affairs', *King Abdulaziz Medical City*. King Faisal Specialist Hospital and Research Centre, 14. doi: 10.1016/j.cmi.2021.12.026.

BPOM (2020a) *Badan Pengawas Obat dan Makanan - Republik Indonesia*. Available at: <https://pom.go.id/new/view/more/pers/565/Tingkatkan-Angka-Kesembuhan-dan-Turunkan-Angka-Kematian-Pasien-COVID-19--Badan-POM-Terbitkan-Izin-Penggunaan-dalam-Kondisi-Darurat-Obat-Favipiravir-dan-Remdesivir.html> (Accessed: 17 April 2022).

BPOM (2020b) 'Keputusan Kepala Badan Pengawas Obat Dan Makanan Nomor Hk_02_02_1_2_03_20_134_Tahun_2020.Pdf'.

BPOM RI (2020) 'Fact Sheet For Health Care Providers Emergency Use Authorization (EUA) Of Favipiravir For Treatment Of COVID-19 Patients', *Badan Pengawas Obat dan Makanan*, pp. 1–17.

Buonaguro, L., Tagliamonte, M., Tornesello, M. L. and Buonaguro, F. M. (2020) 'SARS-CoV-2 RNA polymerase as target for antiviral therapy', *Journal of Translational Medicine*. BioMed Central, 18(1). doi: 10.1186/S12967-020-02355-3.

Cai, Qingxian, Yang, M., Liu, D., Chen, J., Shu, D., Xia, J., Liao, X., Gu, Y., Cai, Qiue, Yang, Y., Shen, C., Li, X., Peng, L., Huang, D., Zhang, J., Zhang, S., Wang, F., Liu, J., Chen, L., Chen, S., Wang, Z., Zhang, Z., Cao, R., Zhong, W., Liu, Y. and Liu, L. (2020) 'Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study', *Engineering*. Elsevier Ltd, 6(10), pp. 1192–1198. doi: 10.1016/j.eng.2020.03.007.

Cascella, M., Rajnik, M., Aleem, A., Dulebohn, S. C. and Napoli, R. Di (2021) 'Features, Evaluation, and Treatment of Coronavirus (COVID-19)', *StatPearls*. StatPearls Publishing. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK554776/> (Accessed: 31 October 2021).

Chen, C., Zhang, Yi, Huang, J., Yin, P., Cheng, Z., Wu, J., Chen, S., Zhang, Yongxi, Chen, B., Lu, M., Luo, Y., Ju, L., Zhang, J. and Wang, X. (2021) 'Favipiravir Versus Arbidol for Clinical Recovery Rate in Moderate and Severe Adult COVID-19 Patients: A Prospective, Multicenter, Open-Label, Randomized Controlled Clinical Trial', *Frontiers in Pharmacology*, 12(September), pp. 1–11. doi:

10.3389/fphar.2021.683296.

Furuta, Y., Komeno, T. and Nakamura, T. (2017) 'Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase', *Proceedings of the Japan Academy. Series B, Physical and Biological Sciences*. The Japan Academy, 93(7), p. 449. doi: 10.2183/PJAB.93.027.

Guan, W., Liang, W., Zhao, Y., Liang, H., Chen, Zi-sheng, Li, Y., Liu, X., Chen, R., Tang, C., Wang, T., Ou, C., Li, L., Chen, P., Sang, L., Wang, W., Li, J., Li, C., Ou, L., Cheng, B., Xiong, S., Ni, Z., Xiang, J., Hu, Yu, Liu, L., Shan, H., Lei, C., Peng, Y., Wei, L., Liu, Y., Hu, Ya-hua, Peng, P., Wang, J., Liu, J., Chen, Zhong, Li, G., Zheng, Z., Qiu, S., Luo, J., Ye, C., Zhu, S., Cheng, L., Ye, F., Li, S., Zheng, J., Zhang, N., Zhong, N. and He, J. (2020) 'Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis', *The European Respiratory Journal*. European Respiratory Society, 55(5), p. 640. doi: 10.1183/13993003.00547-2020.

Harrison, A. G., Lin, T. and Wang, P. (2020) 'Mechanisms of SARS-CoV-2 Transmission and Pathogenesis', *Trends in Immunology*, 41(12), pp. 1100–1115. doi: 10.1016/j.it.2020.10.004.

Hosseinzadeh, R., Sheikh, M. A., Goharrizi, B., Bahardoust, M., Alvanegh, A. G., Ataee, M. R., Bagheri, M., Navidiyan, S., Zijoud, R. H. and Heiat, M. (2021) 'Should all patients with hypertension be worried about developing severe coronavirus disease 2019 (COVID-19)?', *Clinical Hypertension 2021 27:1*. BioMed Central, 27(1), pp. 1–7. doi: 10.1186/S40885-021-00161-7.

Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., Cheng, Z., Yu, T., Xia, J., Wei, Y., Wu, W., Xie, X., Yin, W., Li, H., Liu, M., Xiao, Y., Gao, H., Guo, L., Xie, J., Wang, G., Jiang, R., Gao, Z., Jin, Q., Wang, J. and Cao, B. (2020) 'Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China', *Lancet (London, England)*. Elsevier, 395(10223), p. 497. doi: 10.1016/S0140-6736(20)30183-5.

Jiang, S., Hillyer, C. and Du, L. (2020) 'Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses', *Trends in Immunology*. Elsevier, 41(5),

p. 355. doi: 10.1016/J.IT.2020.03.007.

Jordan, P. C., Stevens, S. K. and Deval, J. (2018) 'Nucleosides for the treatment of respiratory RNA virus infections', *Antiviral Chemistry & Chemotherapy*. SAGE Publications, 26. doi: 10.1177/2040206618764483.

Keputusan Menteri Kesehatan Republik Indonesia (2021) 'Keputusan menteri kesehatan republik indonesia nomor hk.01.07/menkes/5671/2021 tentang manajemen klinis tata laksana', 3, pp. 1–106.

Lim, S., Bae, J. H., Kwon, H. S. and Nauck, M. A. (2020) 'COVID-19 and diabetes mellitus: from pathophysiology to clinical management', *Nature Reviews Endocrinology* 2020 17:1. Nature Publishing Group, 17(1), pp. 11–30. doi: 10.1038/s41574-020-00435-4.

Lippi, G., Wong, J. and Henry, B. M. (2020) 'Hypertension in patients with coronavirus disease 2019 (COVID-19): A pooled analysis', *Polish Archives of Internal Medicine*. Medycyna Praktyczna, 130(4), pp. 304–309. doi: 10.20452/PAMW.15272.

Mikkelsen, M. E. and Abramoff, B. (2022) *COVID-19: Evaluation and management of adults following acute viral illness - UpToDate*. Available at: <https://www.uptodate.com/contents/covid-19-evaluation-and-management-of-adults-following-acute-viral-illness#H385307378> (Accessed: 24 April 2022).

Muhamad, S. A., Ugusman, A., Kumar, J., Skiba, D., Hamid, A. A. and Aminuddin, A. (2021) 'COVID-19 and Hypertension: The What, the Why, and the How', *Frontiers in Physiology*. Frontiers Media S.A., 12, p. 589. doi: 10.3389/FPHYS.2021.665064/BIBTEX.

Ren, L.-L., Wang, Y.-M., Wu, Z.-Q., Xiang, Z.-C., Guo, L., Xu, T., Jiang, Y.-Z., Xiong, Y., Li, Y.-J., Li, X.-W., Li, H., Fan, G.-H., Gu, X.-Y., Xiao, Y., Gao, H., Xu, J.-Y., Yang, F., Wang, X.-M., Wu, C., Chen, L., Liu, Y.-W., Liu, B., Yang, J., Wang, X.-R., Dong, J., Li, L., Huang, C.-L., Zhao, J.-P., Hu, Y., Cheng, Z.-S., Liu, L.-L., Qian, Z.-H., Qin, C., Jin, Q., Cao, B. and Wang, J.-W. (2020) 'Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study', *Chinese Medical Journal*. Wolters Kluwer Health, 133(9), p. 1015. doi:

10.1097/CM9.0000000000000722.

Udwadia, Z. F., Singh, P., Barkate, H., Patil, S., Rangwala, S., Pendse, A., Kadam, J., Wu, W., Caracta, C. F. and Tandon, M. (2020) 'Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial'. doi: 10.1016/j.ijid.2020.11.142.

WHO (2020) *Transmission of SARS-CoV-2: implications for infection prevention precautions*. Available at: <https://www.who.int/news-room/commentaries/detail/transmission-of-sars-cov-2-implications-for-infection-prevention-precautions> (Accessed: 2 September 2021).

WHO (2021) *Naming the coronavirus disease (COVID-19) and the virus that causes it*. Available at: [https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-\(covid-2019\)-and-the-virus-that-causes-it](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it) (Accessed: 29 August 2021).

WHO (2022) *Indonesia: WHO Coronavirus Disease (COVID-19) Dashboard With Vaccination Data | WHO Coronavirus (COVID-19) Dashboard With Vaccination Data*. Available at: <https://covid19.who.int/table> (Accessed: 18 June 2022).

Yang, A.-P., Liu, J.-P., Tao, W.-Q. and Li, H.-M. (2020) 'The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients'. doi: 10.1016/j.intimp.2020.106504.

Zhu, J., Zhong, Z., Ji, P., Li, H., Li, B., Pang, J., Zhang, J. and Zhao, C. (2020) 'Clinicopathological characteristics of 8697 patients with COVID-19 in China: a meta-analysis', *Family Medicine and Community Health*. BMJ Publishing Group, 8(2), p. 406. doi: 10.1136/FMCH-2020-000406.